FDA’s Decision on Vonoprazan Delayed Due to Nitrosamine Impurity
The FDA has established an acceptable daily intake limit for NVP of 96ng/day.
The FDA has established an acceptable daily intake limit for NVP of 96ng/day.
More patients receiving dupilumab have histologic remission, improvement in Dysphagia Symptom Questionnaire scores
The first group received high-dose lirentelimab for 24 weeks. The second group received low-dose lirentelimab, while the placebo group received 6 monthly infusions during the 24-week study.
The MESSINA study included patients 12 to 65 years of age with symptomatic and histologically active EoE.
Among the dupilumab treatment and placebo groups, 69% and 71% had previously used STCs, respectively.
Emergency Use authorization for Novavax vaccine; the Pfizer-BioNTech vaccine gains adolescent approval; submission for oral contraceptive to be switched to over the counter; Astepro nasal spray gets over-the-counter approval; and Dupixent shows benefits in pediatric patients with eosinophilic esophagitis.
The phase 3 EoE KIDS study included 102 children with active eosinophilic esophagitis based on histologic improvement meeting validated histologic criteria.
Stay up-to-date on the latest drugs in development.
The latest guidance for COVID-19 treatment Paxlovid following rebound reports; Dupixent gets a new approval; A new treatment is approved for plaque psoriasis; COVID-19 vaccine efficacy update for those aged under 5; And the latest on Monkeypox.